Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM6TU84)

• Drug Name: Double Oxidized Cysteine Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 6398956
  ChEBI ID: CHEBI:41721
  TTD Drug ID: DM6TU84

Molecule-Related Drug Atlas

Drug(s) Targeting M-phase inducer phosphatase 2 (MPIP2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Avastin+/-Tarceva	DMA86FL	Non-small-cell lung cancer	2C25.Y	Phase 3	[2]
MX-7065	DMP26BW	Solid tumour/cancer	2A00-2F9Z	Terminated	[3]
2-Sulfhydryl-Ethanol	DMJBO3D	Discovery agent	N.A.	Investigative	[1]
Cysteinesulfonic Acid	DMXI8FP	Discovery agent	N.A.	Investigative	[1]
Cysteine Sulfenic Acid	DM4GZUJ	N. A.	N. A.	Investigative	[4]
3-isopropyl-4-(phenylthio)naphthalene-1,2-dione	DMJZEMB	Discovery agent	N.A.	Investigative	[5]
4-(p-toluidino)-3-isopropylnaphthalene-1,2-dione	DMQA0EJ	Discovery agent	N.A.	Investigative	[5]
ADOCIAQUINONE B	DMPOU86	Discovery agent	N.A.	Investigative	[6]
3-isopropyl-4-phenylnaphthalene-1,2-dione	DMYZCWX	Discovery agent	N.A.	Investigative	[5]
4-ethoxynaphthalene-1,2-dione	DMUN7KC	Discovery agent	N.A.	Investigative	[2]

Drug(s) Targeting Staphylococcus Peptide deformylase (Stap-coc def)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
GSK1322322	DM1EPMF	Bacterial infection	1A00-1C4Z	Phase 2	[7]
Actinonin	DMT4P89	N. A.	N. A.	Terminated	[8]
Formic Acid	DMNFZC6	Discovery agent	N.A.	Investigative	[1]
Cysteinesulfonic Acid	DMXI8FP	Discovery agent	N.A.	Investigative	[1]
3-Sulfinoalanine	DMILTRN	N. A.	N. A.	Investigative	[1]
HYDROXY[3-(6-METHYLPYRIDIN-2-YL)PROPYL]FORMAMIDE	DMA4SIN	Discovery agent	N.A.	Investigative	[9]
2-(3-BENZOYLPHENOXY)ETHYL(HYDROXY)FORMAMIDE	DMWMFTJ	Discovery agent	N.A.	Investigative	[9]
[HYDROXY(3-PHENYLPROPYL)AMINO]METHANOL	DM7NXMB	Discovery agent	N.A.	Investigative	[9]
VRC3375	DM1QKVL	Discovery agent	N.A.	Investigative	[10]
N-alkyl urea hydroxamic acids	DM9T0OK	Discovery agent	N.A.	Investigative	[11]

Drug(s) Targeting Alpha-glucosidase (GLA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cipaglucosidase alfa	DMAPDH2	Glycogen storage disease type II	5C51.3	Approved in EU	[12]
Cipaglucosidase alfa	DMAPDH2	Glycogen storage disease type II	5C51.3	Approved in EU	[13]
Deoxynojirimycin	DM2ATZB	Pompe disease	5C51.3	Phase 3	[14]
Anamorelin	DM6HXTS	Carbohydrate metabolism disorder	5C51.Z	Phase 3	[15]
Maltose	DMH0ROP	N. A.	N. A.	Phase 1/2	[4]
AAV2/8-LSPhGAA	DMIX5HF	Pompe disease	5C51.3	Phase 1	[16]
Nicotinamide-Adenine-Dinucleotide	DM9LRKB	N. A.	N. A.	Investigative	[1]
Beta-D-Glucose	DM5IHYP	Discovery agent	N.A.	Investigative	[1]
POP-1	DMVTKCX	Solid tumour/cancer	2A00-2F9Z	Investigative	[17]
JBP-1	DM0KMPN	Solid tumour/cancer	2A00-2F9Z	Investigative	[17]

Drug(s) Targeting Cyclin-dependent kinase 2 (CDK2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
R-roscovitine	DMSH108	Non-small-cell lung cancer	2C25.Y	Phase 2	[18]
Ro 31-7453	DM83QCL	Solid tumour/cancer	2A00-2F9Z	Phase 2	[19]
PHA848125	DMS2Q9G	Thymic cancer	2C27	Phase 2	[20]
TG02	DMZFIGQ	Anaplastic astrocytoma	2A00.0	Phase 1/2	[21]
NUV-422	DMQJQNT	Malignant glioma	2A00.0	Phase 1/2	[22]
RGB-286638	DMEGOQP	Haematological malignancy	2B33.Y	Phase 1	[23]
FN-1501	DM7BMD6	Solid tumour/cancer	2A00-2F9Z	Phase 1	[24]
AG-024322	DMY4WVK	Solid tumour/cancer	2A00-2F9Z	Phase 1	[18]
PHA-793887	DM2Y4FG	Solid tumour/cancer	2A00-2F9Z	Phase 1	[25]
SNS-032	DMEITAS	Solid tumour/cancer	2A00-2F9Z	Phase 1	[26]

Drug(s) Targeting Prolyl endopeptidase (PREP)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
BAICALEIN	DM4C7E6	Influenza virus infection	1E30-1E32	Phase 2	[27]
ALV-003	DMXSFA0	Coeliac disease	DA95	Phase 2	[28]
ONO-1603	DMKIZAL	Cognitive impairment	6D71	Phase 2	[29]
S-17092-1	DMYR1K8	Cognitive impairment	6D71	Phase 1	[30]
JTP-4819	DMI0UJS	Cognitive impairment	6D71	Discontinued in Phase 2	[31]
Z-321	DMLO2QY	Parkinson disease	8A00.0	Discontinued in Phase 1	[32]
BAICALIN	DMY1TLZ	Human immunodeficiency virus infection	1C62	Terminated	[33]
Y-29794	DMLAVES	N. A.	N. A.	Terminated	[33]
Monothioglycerol	DMENSOZ	Discovery agent	N.A.	Investigative	[1]
Z-Pro-Prolinal	DM43O2U	Discovery agent	N.A.	Investigative	[9]

Drug(s) Targeting PTPN1 messenger RNA (PTPN1 mRNA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Hydrogen peroxide	DM1NG5W	Infectious disease	1A00-CA43.1	Approved	[34]
TRYPAN BLUE	DM4NTMO	Ophthalmic surgery injury	PK97	Approved	[35]
URSOLIC ACID	DM4SOAW	Metabolic syndrome x	5C50-5D2Z	Phase 2	[36]
ISIS 113715	DMUPD4G	Type-2 diabetes	5A11	Phase 2	[37]
ISIS-PTP1Brx	DMJGVXT	Type-2 diabetes	5A11	Phase 2	[38]
ERTIPROTAFIB	DMJXEV7	Type-2 diabetes	5A11	Terminated	[39]
Acetate Ion	DMD08RH	Discovery agent	N.A.	Investigative	[1]
B-Octylglucoside	DMMO75G	Discovery agent	N.A.	Investigative	[1]
2-Methyl-2,4-Pentanediol	DMD45CU	Discovery agent	N.A.	Investigative	[1]
1,2-NAPHTHOQUINONE	DMYXELH	Discovery agent	N.A.	Investigative	[40]

Drug(s) Targeting Intestinal maltase-glucoamylase (MGAM)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Voglibose	DMUBP9O	Diabetic complication	5A2Y	Approved	[41]
Acarbose	DMRM3AW	Diabetic complication	5A2Y	Approved	[42]
Miglitol	DMXBQAM	Diabetic complication	5A2Y	Approved	[43]
Rh-alphaglucosidase	DMNF0G8	Pompe disease	5C51.3	Approved	[44]
Deoxynojirimycin	DM2ATZB	Pompe disease	5C51.3	Phase 3	[14]
Alpha-glucosidase	DM2RTGP	Muscle disease	FB3Z	Phase 3	[45]
PAZ-320	DMU0812	Type-2 diabetes	5A11	Phase 2	[46]
SC-49483	DM180VX	Acquired immune deficiency syndrome	1C62.3	Phase 2	[47]
Maltose	DMH0ROP	N. A.	N. A.	Phase 1/2	[4]
SALACINOL	DMVKQT8	N. A.	N. A.	Phase 1/2	[48]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Alpha-glucosidase (GLA)	TTHCF4J	LYAG_HUMAN; GANAB_HUMAN; GANC_HUMAN	Inhibitor	[1]
Beta-crystallin B1 (CRYBB1)	TTDS503	CRBB1_HUMAN	Inhibitor	[1]
Cyclin-dependent kinase 2 (CDK2)	TT7HF4W	CDK2_HUMAN	Inhibitor	[1]
Intestinal maltase-glucoamylase (MGAM)	TTXWASR	MGA_HUMAN	Inhibitor	[1]
M-phase inducer phosphatase 2 (MPIP2)	TTR0SWN	MPIP2_HUMAN	Inhibitor	[1]
Prolyl endopeptidase (PREP)	TTNGKET	PPCE_HUMAN	Inhibitor	[1]
PTPN1 messenger RNA (PTPN1 mRNA)	TTELIN2	PTN1_HUMAN	Inhibitor	[1]
Staphylococcus Peptide deformylase (Stap-coc def)	TTICO5G	DEF_STAAU	Inhibitor	[1]

References

• [1] How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
• [2] Bioactivities of simplified adociaquinone B and naphthoquinone derivatives against Cdc25B, MKP-1, and MKP-3 phosphatases. Bioorg Med Chem. 2009 Mar 15;17(6):2276-81.
• [3] Handbook of Assay Development in Drug Discovery, Lisa K. Minor, 2013. Page(11).
• [4] DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011 Jan;39(Database issue):D1035-41.
• [5] Synthesis of miltirone analogues as inhibitors of Cdc25 phosphatases. Bioorg Med Chem Lett. 2006 Apr 1;16(7):1905-8.
• [6] Novel naphthoquinone and quinolinedione inhibitors of CDC25 phosphatase activity with antiproliferative properties. Bioorg Med Chem. 2008 Oct 1;16(19):9040-9.
• [7] Peptide deformylase: a new target in antibacterial, antimalarial and anticancer drug discovery. Curr Med Chem. 2015;22(2):214-36.
• [8] Actinonin, a naturally occurring antibacterial agent, is a potent deformylase inhibitor. Biochemistry. 2000 Feb 15;39(6):1256-62.
• [9] The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
• [10] Peptide deformylase inhibitors as antibacterial agents: identification of VRC3375, a proline-3-alkylsuccinyl hydroxamate derivative, by using an integrated combinatorial and medicinal chemistry approach. Antimicrob Agents Chemother. 2004 Jan;48(1):250-61.
• [11] N-alkyl urea hydroxamic acids as a new class of peptide deformylase inhibitors with antibacterial activity. Antimicrob Agents Chemother. 2002 Sep;46(9):2752-64.
• [12] Cipaglucosidase Alfa: First Approval. Drugs. 2023 Jun;83(8):739-745.
• [13] FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 761204
• [14] Nitrogen-in-the-ring pyranoses and furanoses: structural basis of inhibition of mammalian glycosidases. J Med Chem. 1994 Oct 28;37(22):3701-6.
• [15] Absorption, elimination, and metabolism of CS-1036, a novel -amylase inhibitor in rats and monkeys, and the relationship between gastrointestinal distribution and suppression of glucose absorption.Drug Metab Dispos.2013 Apr;41(4):878-87.
• [16] ClinicalTrials.gov (NCT03533673) AAV2/8-LSPhGAA in Late-Onset Pompe Disease. U.S. National Institutes of Health.
• [17] US patent application no. 2012,0251,516, PHARMACEUTICAL COMPOSITION FOR TREATING CANCER COMPRISING TRYPSINOGEN AND/OR CHYMOTRYPSINOGEN AND AN ACTIVE AGENT SELECTED FROM A SELENIUM COMPOUND, A VANILLOID COMPOUND AND A CYTOPLASMIC GLYCOLYSIS REDUCTION AGENT.
• [18] Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009 Jul;8(7):547-66.
• [19] A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
• [20] Identification of N,1,4,4-tetramethyl-8-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide (PHA-848125), a potent, orally available cyclin dependent kinase inhibitor. J Med Chem. 2009 Aug 27;52(16):5152-63.
• [21] Preclinical metabolism and pharmacokinetics of SB1317 (TG02), a potent CDK/JAK2/FLT3 inhibitor. Drug Metab Lett. 2012 Mar;6(1):33-42.
• [22] ClinicalTrials.gov (NCT04541225) Phase 1/2 Dose Escalation, Safety, Pharmacokinetics, and Efficacy Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid Tumors. U.S.National Institutes of Health.
• [23] Small-molecule multi-targeted kinase inhibitor RGB-286638 triggers P53-dependent and -independent anti-multiple myeloma activity through inhibition of transcriptional CDKs. Leukemia. 2013 Dec;27(12):2366-75.
• [24] Discovery of 4-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-N-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-1H-pyrazole-3-carboxamide (FN-1501), an FLT3- and CDK-Kinase Inhibitor with Potentially High Efficiency against Acute Myelocytic Leukemia. J Med Chem. 2018 Feb 22;61(4):1499-1518.
• [25] A first in man, phase I dose-escalation study of PHA-793887, an inhibitor of multiple cyclin-dependent kinases (CDK2, 1 and 4) reveals unexpected h... Cell Cycle. 2011 Mar 15;10(6):963-70.
• [26] Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia. Blood. 2009 May 7;113(19):4637-45.
• [27] Baicalin, a prodrug able to reach the CNS, is a prolyl oligopeptidase inhibitor. Bioorg Med Chem. 2008 Aug 1;16(15):7516-24.
• [28] The effects of ALV003 pre-digestion of gluten on immune response and symptoms in celiac disease in vivo. Clin Immunol. 2010 Mar;134(3):289-95.
• [29] ONO-1603, a potential antidementia drug, shows neuroprotective effects and increases m3-muscarinic receptor mRNA levels in differentiating rat cerebellar granule neurons. Neurosci Lett. 1996 Aug 23;214(2-3):151-4.
• [30] Effect of S 17092, a novel prolyl endopeptidase inhibitor, on substance P and alpha-melanocyte-stimulating hormone breakdown in the rat brain. J Neurochem. 2003 Mar;84(5):919-29.
• [31] A novel prolyl endopeptidase inhibitor, JTP-4819, with potential for treating Alzheimer's disease. Behav Brain Res. 1997 Feb;83(1-2):147-51.
• [32] Z-321, a prolyl endopeptidase inhibitor, augments the potentiation of synaptic transmission in rat hippocampal slices. Behav Brain Res. 1997 Feb;83(1-2):213-6.
• [33] Inhibitors of prolyl oligopeptidases for the therapy of human diseases: defining diseases and inhibitors. J Med Chem. 2010 May 13;53(9):3423-38.
• [34] Periodinates: a new class of protein tyrosine phosphatase inhibitors. Bioorg Med Chem Lett. 1999 Feb 8;9(3):353-6.
• [35] Evans Blue and other dyes as protein tyrosine phosphatase inhibitors. Bioorg Med Chem Lett. 2004 Apr 19;14(8):1923-6.
• [36] Cytotoxic and PTP1B inhibitory activities from Erythrina abyssinica. Bioorg Med Chem Lett. 2009 Dec 1;19(23):6745-9.
• [37] Clinical pipeline report, company report or official report of ISIS Pharmaceuticals (2009).
• [38] Clinical pipeline report, company report or official report of ISIS Pharmaceuticals.
• [39] 2-O-carboxymethylpyrogallol derivatives as PTP1B inhibitors with antihyperglycemic activity. Bioorg Med Chem Lett. 2007 Oct 1;17(19):5357-60.
• [40] Synthesis and PTP1B inhibition of 1,2-naphthoquinone derivatives as potent anti-diabetic agents. Bioorg Med Chem Lett. 2002 Aug 5;12(15):1941-6.
• [41] Effects of changeover from voglibose to acarbose on postprandial triglycerides in type 2 diabetes mellitus patients. Adv Ther. 2009 Jun;26(6):660-6.
• [42] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [43] Drug therapy of postprandial hyperglycaemia. Drugs. 1999 Jan;57(1):19-29.
• [44] 2006 drug approvals: finding the niche. Nat Rev Drug Discov. 2007 Feb;6(2):99-101.
• [45] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2627).
• [46] Treatment With Novel Galactomannan Derivative Reduces 2-Hour Postprandial Glucose Excursions in Individuals With Type 2 Diabetes Treated With Oral Medications and/or Insulin. J Diabetes Sci Technol. 2014 September; 8(5): 1018-1022.
• [47] Pathology of perbutylated-N-butyl-1-deoxynojiromycin (an alpha-glucosidase-1 inhibitor) in Sprague-Dawley rats. Toxicol Pathol. 1996 Sep-Oct;24(5):531-8.
• [48] Probing the active-site requirements of human intestinal N-terminal maltase-glucoamylase: Synthesis and enzyme inhibitory activities of a six-membe... Bioorg Med Chem. 2010 Nov 15;18(22):7794-8.